OTC clemastine data shows significant improvement in cold symptoms versus placebo.
This article was originally published in The Tan Sheet
Executive Summary
OTC CLEMASTINE DATA SHOWS "SIGNIFICANT" IMPROVEMENT IN COLD SYMPTOMS compared to placebo, Sandoz Clinical Research & Medical Affairs Associate Director Lori Beth Cirangle, MD, reported at a Nov. 16 meeting of FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees. The session was held to determine whether pre-NDA data submitted by Sandoz that included two clinical studies support a common cold indication for 1.34 mg clemastine fumarate .
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning